These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 23630346)

  • 1. Catecholamine-Induced β2-adrenergic receptor activation mediates desensitization of gastric cancer cells to trastuzumab by upregulating MUC4 expression.
    Shi M; Yang Z; Hu M; Liu D; Hu Y; Qian L; Zhang W; Chen H; Guo L; Yu M; Song L; Ma Y; Guo N
    J Immunol; 2013 Jun; 190(11):5600-8. PubMed ID: 23630346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The β2-adrenergic receptor and Her2 comprise a positive feedback loop in human breast cancer cells.
    Shi M; Liu D; Duan H; Qian L; Wang L; Niu L; Zhang H; Yong Z; Gong Z; Song L; Yu M; Hu M; Xia Q; Shen B; Guo N
    Breast Cancer Res Treat; 2011 Jan; 125(2):351-62. PubMed ID: 20237834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and characterization of a preclinical ovarian carcinoma model to investigate the mechanism of acquired resistance to trastuzumab.
    Luistro LL; Rosinski JA; Bian H; Bishayee S; Rameshwar P; Ponzio NM; Ritland SR
    Int J Oncol; 2012 Aug; 41(2):639-51. PubMed ID: 22580986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. β2-AR signaling controls trastuzumab resistance-dependent pathway.
    Liu D; Yang Z; Wang T; Yang Z; Chen H; Hu Y; Hu C; Guo L; Deng Q; Liu Y; Yu M; Shi M; Du N; Guo N
    Oncogene; 2016 Jan; 35(1):47-58. PubMed ID: 25798840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feedback activation of STAT3 mediates trastuzumab resistance via upregulation of MUC1 and MUC4 expression.
    Li G; Zhao L; Li W; Fan K; Qian W; Hou S; Wang H; Dai J; Wei H; Guo Y
    Oncotarget; 2014 Sep; 5(18):8317-29. PubMed ID: 25327561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
    Mercogliano MF; De Martino M; Venturutti L; Rivas MA; Proietti CJ; Inurrigarro G; Frahm I; Allemand DH; Deza EG; Ares S; Gercovich FG; Guzmán P; Roa JC; Elizalde PV; Schillaci R
    Clin Cancer Res; 2017 Feb; 23(3):636-648. PubMed ID: 27698002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
    Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
    Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
    Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic reovirus combined with trastuzumab enhances antitumor efficacy through TRAIL signaling in human HER2-positive gastric cancer cells.
    Hamano S; Mori Y; Aoyama M; Kataoka H; Tanaka M; Ebi M; Kubota E; Mizoshita T; Tanida S; Johnston RN; Asai K; Joh T
    Cancer Lett; 2015 Jan; 356(2 Pt B):846-54. PubMed ID: 25444894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer.
    Barok M; Tanner M; Köninki K; Isola J
    Cancer Lett; 2011 Jul; 306(2):171-9. PubMed ID: 21458915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
    Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
    Wainberg ZA; Anghel A; Desai AJ; Ayala R; Luo T; Safran B; Fejzo MS; Hecht JR; Slamon DJ; Finn RS
    Clin Cancer Res; 2010 Mar; 16(5):1509-19. PubMed ID: 20179222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Catecholamine up-regulates MMP-7 expression by activating AP-1 and STAT3 in gastric cancer.
    Shi M; Liu D; Duan H; Han C; Wei B; Qian L; Chen C; Guo L; Hu M; Yu M; Song L; Shen B; Guo N
    Mol Cancer; 2010 Oct; 9():269. PubMed ID: 20939893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models.
    Fujimoto-Ouchi K; Sekiguchi F; Yasuno H; Moriya Y; Mori K; Tanaka Y
    Cancer Chemother Pharmacol; 2007 May; 59(6):795-805. PubMed ID: 17031648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. β2-AR activation promotes cleavage and nuclear translocation of Her2 and metastatic potential of cancer cells.
    Liu D; Zha L; Liu Y; Zhao X; Xu X; Liu S; Ma W; Zheng J; Shi M
    Cancer Sci; 2020 Dec; 111(12):4417-4428. PubMed ID: 33016509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway.
    Du C; Yi X; Liu W; Han T; Liu Z; Ding Z; Zheng Z; Piao Y; Yuan J; Han Y; Xie M; Xie X
    BMC Cancer; 2014 Nov; 14():869. PubMed ID: 25417825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer.
    Kim HP; Han SW; Song SH; Jeong EG; Lee MY; Hwang D; Im SA; Bang YJ; Kim TY
    Oncogene; 2014 Jun; 33(25):3334-41. PubMed ID: 23873022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-expression of erythropoietin receptor with human epidermal growth factor 2 may counteract trastuzumab inhibition in gastric cancer.
    Li R; Yuan L; Wang J; Wang J
    Med Hypotheses; 2011 Dec; 77(6):948-52. PubMed ID: 21944379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucolytic Agents Can Enhance HER2 Receptor Accessibility for [(89)Zr]Trastuzumab, Improving HER2 Imaging in a Mucin-Overexpressing Breast Cancer Xenograft Mouse Model.
    Wimana Z; Gebhart G; Guiot T; Vanderlinden B; Morandini R; Doumont G; Sherer F; Van Simaeys G; Goldman S; Ghanem G; Flamen P
    Mol Imaging Biol; 2015 Oct; 17(5):697-703. PubMed ID: 25761907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. β2-AR activation induces chemoresistance by modulating p53 acetylation through upregulating Sirt1 in cervical cancer cells.
    Chen H; Zhang W; Cheng X; Guo L; Xie S; Ma Y; Guo N; Shi M
    Cancer Sci; 2017 Jul; 108(7):1310-1317. PubMed ID: 28498637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.